Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

Video

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Patients who are refractory to chemotherapy now have CAR T-cell therapy as an option, according to Karmali. The SCHOLAR-1 study investigated the outcomes of patients with refractory DLBCL, which showed a median overall survival of 6 months. The addition of CAR T-cell therapy has benefitted this patient population, says Karmali.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.